Delcath Systems, Inc. announces the expansion of its global Phase 2 program for the treatment of patients with unresectable hepatocellular carcinoma (HCC) or primary liver cancer.
from The Medical News http://ift.tt/1O3yCt4
from The Medical News http://ift.tt/1O3yCt4
No comments:
Post a Comment